{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:23:52Z","timestamp":1788521032166,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008667","name":"National Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008667","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.clbc.2023.03.011","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T03:11:20Z","timestamp":1680145880000},"page":"500-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the Necessity for Routine Sentinel Lymph Node Biopsy in Postmenopausal Patients Being Treated for Clinically Node Negative Breast Cancer the Era of RxPONDER"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9920","authenticated-orcid":false,"given":"Matthew G.","family":"Davey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin P.","family":"Kerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray P.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel M.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami Abd","family":"Elwahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife J.","family":"Lowery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Kerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2023.03.011_bib0001","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0002","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.03.011_bib0003","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van't Veer","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2023.03.011_bib0004","first-page":"393","article-title":"Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer","volume":"9","author":"McVeigh","year":"2017","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2023.03.011_bib0005","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/tbj.14217","article-title":"Clinicopathological correlates, oncological impact, and validation of Oncotype DX\u2122 in a European Tertiary Referral Centre","volume":"27","author":"Davey","year":"2021","journal-title":"Breast J"},{"key":"10.1016\/j.clbc.2023.03.011_bib0006","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","article-title":"Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer","volume":"24","author":"Paik","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0007","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-022-06580-w","article-title":"Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis","volume":"193","author":"Davey","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2023.03.011_bib0008","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clbc.2023.03.011_bib0009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clbc.2023.03.011_bib0010","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-018-4820-0","article-title":"Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes","volume":"171","author":"Andersson","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2023.03.011_bib0011","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0012","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JCO.2016.71.0947","article-title":"Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice guideline update","volume":"35","author":"Lyman","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0013","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4048\/jbc.2017.20.3.217","article-title":"Sentinel lymph node biopsy in breast cancer: a clinical review and update","volume":"20","author":"Zahoor","year":"2017","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.clbc.2023.03.011_bib0014","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1200\/JCO.2000.18.13.2553","article-title":"Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer","volume":"18","author":"Giuliano","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0015","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa012782","article-title":"A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer","volume":"349","author":"Veronesi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.03.011_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/11782234211022203","article-title":"Evaluating the clinical utility of routine sentinel lymph node biopsy and the value of adjuvant chemotherapy in elderly patients diagnosed with oestrogen receptor positive, clinically node negative breast cancer","volume":"15","author":"Davey","year":"2021","journal-title":"Breast Cancer (Auckl)"},{"key":"10.1016\/j.clbc.2023.03.011_bib0017","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial","volume":"305","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2023.03.011_bib0018","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0019","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.canrad.2021.11.013","article-title":"Radiotherapy of breast cancer","volume":"26","author":"Hennequin","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.clbc.2023.03.011_bib0020","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0021","doi-asserted-by":"crossref","first-page":"452","DOI":"10.6004\/jnccn.2020.0016","article-title":"Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Gradishar","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 6","key":"10.1016\/j.clbc.2023.03.011_bib0022","doi-asserted-by":"crossref","first-page":"vi7","DOI":"10.1093\/annonc\/mdt284","article-title":"Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Senkus","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0023","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2023.03.011_bib0024","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0025","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1038\/modpathol.2010.55","article-title":"Issues and updates: evaluating estrogen receptor-\u03b1, progesterone receptor, and HER2 in breast cancer","volume":"23","author":"Allred","year":"2010","journal-title":"Modern Pathol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0026","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/modpathol.3800388","article-title":"Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index","volume":"18","author":"Meyer","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0027","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"10.1016\/j.clbc.2023.03.011_bib0028","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.3390\/cancers13174455","article-title":"Ki-67 as a prognostic biomarker in invasive breast cancer","volume":"13","author":"Davey","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clbc.2023.03.011_bib0029","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12874-017-0436-z","article-title":"New methods for estimating follow-up rates in cohort studies","volume":"17","author":"Xue","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5395\/rde.2017.42.2.152","article-title":"Statistical notes for clinical researchers: chi-squared test and Fisher's exact test","volume":"42","author":"Kim","year":"2017","journal-title":"Restor Dent Endod"},{"key":"10.1016\/j.clbc.2023.03.011_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2021.101531","article-title":"Disease recurrence and oncological outcome of patients treated surgically with curative intent for estrogen receptor positive, lymph node negative breast cancer","volume":"37","author":"Davey","year":"2021","journal-title":"Surg Oncol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0032","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jnci\/89.22.1673","article-title":"Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer","volume":"89","author":"Fisher","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2023.03.011_bib0033","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/tbj.13483","article-title":"Increasing omission of radiation therapy and sentinel node biopsy in elderly patients with early stage, hormone-positive breast cancer","volume":"26","author":"Christian","year":"2020","journal-title":"Breast J"},{"key":"10.1016\/j.clbc.2023.03.011_bib0034","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/j.clbc.2021.02.011","article-title":"The impact of genomic profiling on adjuvant therapy recommendation in postmenopausal women with ER-positive, T1-2 breast cancer: can genomic profiling eliminate the need for sentinel lymph node biopsy?","volume":"21","author":"Lee","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2023.03.011_bib0035","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1245\/s10434-021-09839-6","article-title":"Sentinel node biopsy should not be routine in older patients with ER-positive HER2-negative breast cancer who are willing and able to take hormone therapy","volume":"28","author":"McKevitt","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0036","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.breast.2012.06.013","article-title":"Abandoning sentinel lymph node biopsy in early breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND: Sentinel node vs Observation after axillary UltraSouND)","volume":"21","author":"Gentilini","year":"2012","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2023.03.011_bib0037","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0042-122853","article-title":"Restricted axillary staging in clinically and sonographically node-negative early invasive breast cancer (c\/iT1-2) in the context of breast conserving therapy: first results following commencement of the Intergroup-Sentinel-Mamma (INSEMA) trial","volume":"77","author":"Reimer","year":"2017","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.clbc.2023.03.011_bib0038","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10549-022-06671-8","article-title":"Using menopause status and 21-gene expression assay to inform chemotherapy benefit in node-positive breast cancer","volume":"195","author":"Davey","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2023.03.011_bib0039","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/01.sla.0000245472.47748.ec","article-title":"Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients","volume":"245","author":"Langer","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.clbc.2023.03.011_bib0040","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.amjsurg.2019.08.004","article-title":"Are we choosing wisely in elderly females with breast cancer?","volume":"218","author":"Calderon","year":"2019","journal-title":"Am J Surg"},{"key":"10.1016\/j.clbc.2023.03.011_bib0041","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41523-022-00383-4","article-title":"De-escalation in breast cancer surgery","volume":"8","author":"Shubeck","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.clbc.2023.03.011_bib0042","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamasurg.2020.0322","article-title":"Deimplementation of the choosing wisely recommendations for low-value breast cancer surgery: a systematic review","volume":"155","author":"Wang","year":"2020","journal-title":"JAMA Surg"},{"key":"10.1016\/j.clbc.2023.03.011_bib0043","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.3390\/curroncol29070403","article-title":"Choosing wisely-barriers and solutions to implementation in low and middle-income countries","volume":"29","author":"Rubagumya","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clbc.2023.03.011_bib0044","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.breast.2021.02.001","article-title":"Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - a systematic review and meta-analysis","volume":"56","author":"Davey","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2023.03.011_bib0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.surge.2016.09.007","article-title":"The impact of the biomolecular era on breast cancer surgery","volume":"15","author":"McVeigh","year":"2017","journal-title":"Surgeon"},{"key":"10.1016\/j.clbc.2023.03.011_bib0046","doi-asserted-by":"crossref","first-page":"c214","DOI":"10.1159\/000235241","article-title":"Cohort studies: prospective versus retrospective","volume":"113","author":"Euser","year":"2009","journal-title":"Nephron Clin Pract"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:25:20Z","timestamp":1761513920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820923000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1526820923000800"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2023.03.011","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the Necessity for Routine Sentinel Lymph Node Biopsy in Postmenopausal Patients Being Treated for Clinically Node Negative Breast Cancer the Era of RxPONDER","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2023.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}